Provided are a method of preparing a metal oxide-silica composite aerogel, and a metal oxide-silica composite aerogel having an excellent weight reduction property prepared by the method. The method includes a step of adding an acid catalyst to a first water glass solution to prepare an acidic water glass solution (step 1); a step of adding a metal ion solution to the acidic water glass solution to prepare a precursor solution (step 2); and a step of adding a second water glass solution to the precursor solution and performing a gelation reaction (step 3) to yield a metal oxide-silica composite wet gel, wherein, in steps 2 and 3, bubbling of an inert gas is performed during the adding of the metal ion solution or the second water glass solution, respectively.

A nanostructure is provided that in one embodiment includes a cluster of cylindrical bodies. Each of the cylindrical bodies in the cluster are substantially aligned with one another so that their lengths are substantially parallel. The composition of the cylindrical bodies include tungsten (W) and sulfur (S), and each of the cylindrical bodies has a geometry with at least one dimension that is in the nanoscale. Each cluster of cylindrical bodies may have a width dimension ranging from 0.2 microns to 5.0 microns, and a length greater than 5.0 microns. In some embodiments, the cylindrical bodies are composed of tungsten disulfide (WS.sub.2). In another embodiment the nanolog is a particle comprised of external concentric disulfide layers which encloses internal disulfide folds and regions of oxide. Proportions between disulfide and oxide can be tailored by thermal treatment and/or extent of initial synthesis reaction.

The present invention relates to a magnetic resonance imaging (MRI) contrast agent, particularly a metal oxide nanoparticle-based T1-T2 dual-mode MRI contrast agent that can be used not only as a T1 MRI contrast agent but also as a T2 MRI contrast agent, and a method for producing the same. The metal oxide nanoparticle-based T1-T2 dual-mode MRI contrast agent can provide more accurate and detailed information associated with disease than single MRI contrast agent by the beneficial contrast effects in both T1 imaging with high tissue resolution and T2 imaging with high feasibility on detection of a lesion.

Disclosed is a catalyst for oxygen reduction and evolution reactions. The catalyst is in the form of nickel sulfide (NiS.sub.2) nanosheets. NiS.sub.2 molecules are cross-linked and oriented two-dimensionally in the NiS.sub.2 nanosheets. Also disclosed is a method for producing the catalyst.

The present invention provides a composite oxide that can achieve a high low-temperature output characteristic, a method for manufacturing the same, and a positive electrode active material in which the generation of soluble lithium is suppressed and a problem of gelation is not caused during the paste preparation. A positive electrode active material for non-aqueous electrolyte secondary batteries, including a lithium-metal composite oxide powder including a secondary particle configured by aggregating primary particles containing lithium, nickel, manganese, and cobalt, or a lithium-metal composite oxide powder including both the primary particles and the secondary particle. The secondary particle has a porous structure inside as a main inside structure, the slurry pH is 11.5 or less, the soluble lithium content rate is 0.5[% by mass] or less, the specific surface area is 3.0 to 4.0 [m.sup.2/g], and the porosity is more than 50 to 80[%].

Disclosed is an ink including at least one particle including a first material; and at least one liquid vehicle; wherein the particle includes at least one particle including a second material and at least one nanoparticle dispersed in the second material; wherein the first material and the second material have an extinction coefficient less or equal to 1510.sup.5 at 460 nm. The invention also relates to inks, light emitting materials including at least one ink, patterns including at least one ink, particles deposited on a support, optoelectronic devices including at least one ink and method for depositing an ink on a support.

A process of preparing polycrystalline group III nitride chunks comprising the steps of (a) placing a group III metal inside a source chamber; (b) flowing a halogen-containing gas over the group III metal to form a group III metal halide; (c) contacting the group III metal halide with a nitrogen-containing gas in a deposition chamber containing a foil, the foil comprising at least one of Mo, W, Ta, Pd, Pt, Ir, or Re; (d) forming a polycrystalline group III nitride layer on the foil within the deposition chamber; (e) removing the polycrystalline group III nitride layer from the foil; and (f) comminuting the polycrystalline group III nitride layer to form the polycrystalline group III nitride chunks, wherein the removing and the comminuting are performed in any order or simultaneously.

The present invention provides an amphiphilic molecular sieve containing a hydrophilic group on the outside and a lipophilic group on the inside and a production method thereof. The production method comprises: dispersing the ZSM-5 spherical nano-molecular sieve into toluene, adding thereto an organosilane containing a hydrophilic group and reacting at 40-80 C. for 2-16 h, to obtain a molecular sieve containing a hydrophilic group; placing the molecular sieve containing a hydrophilic group in an aqueous solution of sodium hydroxide and reacting at 50-90 C. for 10-50 min, to obtain a molecular sieve containing a hydrophilic group on the outside; dispersing the molecular sieve containing a hydrophilic group on the outside into toluene, adding thereto an organosilane containing a lipophilic group and reacting at 40-80 C. for 2-12 h, to obtain the amphiphilic molecular sieve containing a hydrophilic group on the outside and a lipophilic group on the inside. The present invention also provides an amphiphilic molecular sieve obtained by the above production method, which contains a hydrophilic group on the outside and a lipophilic group on the inside.

Disclosed are a pharmaceutical use of a gold cluster and a substance containing the gold cluster and the preparation method and use thereof. The gold cluster and substance containing the gold cluster can inhibit the aggregation of A and -syn, has excellent effects on the levels of cell models and animal models, and can be used to prepare drugs for preventing and treating Alzheimer's disease and/or Parkinson's disease.

A nanostructure is provided that in one embodiment includes a cluster of cylindrical bodies. Each of the cylindrical bodies in the cluster are substantially aligned with one another so that their lengths are substantially parallel. The composition of the cylindrical bodies include tungsten (W) and sulfur (S), and each of the cylindrical bodies has a geometry with at least one dimension that is in the nanoscale. Each cluster of cylindrical bodies may have a width dimension ranging from 0.2 microns to 5.0 microns, and a length greater than 5.0 microns. In some embodiments, the cylindrical bodies are composed of tungsten disulfide (WS2). In another embodiment the nanolog is a particle comprised of external concentric disulfide layers which encloses internal disulfide folds and regions of oxide. Proportions between disulfide and oxide can be tailored by thermal treatment and/or extent of initial synthesis reaction.